Antigen-Specific Peptide Immunotherapy for Type 1 Diabetes: Proof of Safety, Hope for Efficacy
- PMID: 28978425
- DOI: 10.1016/j.cmet.2017.09.016
Antigen-Specific Peptide Immunotherapy for Type 1 Diabetes: Proof of Safety, Hope for Efficacy
Abstract
Antigen-specific immunotherapy has long been hailed as the ideal disease-modifying approach for type 1 diabetes, both for disease prevention and reversal. A small phase 1 trial now demonstrates safety of a peptide-based treatment in recently diagnosed adults.
Copyright © 2017. Published by Elsevier Inc.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical